Andrew and Patel Associates

Camp Hill, Pennsylvania 17011

0 studies enrolling now · 2 studies all time

What they study most

Carcinoma, Non-Small-Cell Lung, Tumors With Aberrations in ALK or ROS1

Studies at this site

• Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1) — Completed
• Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE) — Stopped early